SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in its Charter)
|(State or Other
|(Commission File Number)||(I.R.S.
Employer Identification |
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading
|Name of each exchange|
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 7.01.||Regulation FD Disclosure.|
The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Members of the Theravance Biopharma, Inc. management team will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022 and at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, and from September 13-15, 2022, conducting one-on-one meetings with analysts and investors during the conferences using a slide presentation which is being furnished pursuant to Regulation FD as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|Item 9.01.||Financial Statements and Exhibits.|
|99.1||Slide deck entitled Transformed and Focused on Medicines that Make a Difference®|
|104||Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|THERAVANCE BIOPHARMA, INC.|
|Date: September 13, 2022||By: /s/ Andrew Hindman|
|Senior Vice President and Chief Financial Officer|
THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Transformed and Focused on Medicines that Make a Difference ® September 12, 2022 © 2022 Theravance Biopharma. All rights reserved.
Forward - looking Statements This presentation contains certain "forward - looking" statements as that term is defined in the Private Securities Litigation Ref orm Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (th e “ Company”) intends such forward - looking statements to be covered by the safe harbor provisions for forward - looking statements contained in Section 21E of the Se curities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: contingent payments due to the Company from the sale of the Compa ny’ s TRELEGY ELLIPTA royalty interests to Royalty Pharma, the Company's goals, designs, strategies, plans and objectives, including the paydown of the Compan y’s debt, the impact of the Company’s restructuring plan, ability to provide value to shareholders, the timing of clinical studies, the potential that th e C ompany's research programs will progress product candidates into the clinic, the Company's expectations regarding its allocation of resources, potential regu lat ory actions, product sales or profit share revenue and the Company's expectations for its future financial performance and expectations as to future cash flows. T hes e statements are based on the current estimates and assumptions of the management of the Company as of the date of this presentation and are subject to ris ks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of the Company to be materially different from th ose reflected in the forward - looking statements. Important factors that could cause actual results to differ materially from those indicated by such forwa rd - looking statements include, among others, risks related to: whether the milestone thresholds can be achieved, delays or difficulties in commencing, enrolling o r c ompleting clinical studies, the potential that results from clinical or non - clinical studies indicate the Company's product candidates are unsafe, ineffective o r not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, del ays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, ma nuf acture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate techni cal expertise and supporting infrastructure, ability to retain key personnel, the impact of the Company’s restructuring actions on its employees, partners an d others. In addition, while we expect the effects of COVID - 19 to continue to adversely impact our business operations and financial results, the extent of the impact on our ability to generate revenue from YUPELRI® ( revefenacin ), and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cann ot be predicted with confidence at this time. Other risks affecting the Company are in the Company's Form 10 - Q filed with the SEC on August 8, 2022, and other periodic report s filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also cou ld affect Theravance Biopharma's results. No forward - looking statements can be guaranteed, and actual results may differ materially from such stateme nts. Given these uncertainties, you should not place undue reliance on these forward - looking statements. Theravance Biopharma assumes no obligation to update it s forward - looking statements on account of new information, future events or otherwise, except as required by law. 2
Theravance Biopharma At - a - Glance 3 MSA, multiple system atrophy; PIFR, peak inspiratory flow rate. • Commercial product poised for significant near - term growth • YUPELRI PIFR - 2 Phase 4 • Phase 3 potential therapy for MSA patients with opportunity to differentiate from existing treatment options • $25 million investment from Royalty Pharma to fund majority of Phase 3 costs • Debt - free balance sheet • Finalizing capital return program • On track to be cash flow positive by 2023 • Mid - to long - term value from milestone and outer - year royalties Ampreloxetine Retained Value Experienced Board and Management team with the right mix of skills and experience to drive value Financials
Free Cash Flow High cash burn Decreased cash burn Expect to be cash flow positive by 2023 Capital Structure $230M Convertible Senior Notes $420M Non - recourse TRELEGY Notes Debt - free Finalizing capital return program YUPELRI ® Slow launch due to pandemic headwinds Significant growth opportunities PIFR - 2 Phase 4 Study Theravance Biopharma Transformation 4 1. 85% of TRELEGY ELLIPTA royalties return to Theravance Biopharma beginning July 1, ௗ 2029 ௗ for sales ex - U.S., and January 1, ௗ 2031 ௗ for sales within the U.S. Net present value (“NPV”) of royalties based on GSK Bloomberg Consensus for TRELEGY ELLIPTA through 2032 for U.S. sales and through 2034 for ex - U. S. sales, discounted at 7%. Ex - U.S. sales for 2033 - 2034 extrapolated by Management due to limitation of consensus beyond 2032. Pre - restructure Today: Focused Pipeline Focus Multiple programs Ampreloxetine ~$1.1B upfront Up to $250M in milestone value ~$200M 1 in outer - year royalty value TRELEGY Timely realization of value uncertain
Investment Highlights • Transformed and focused therapeutics company • Attractive pipeline and programs with YUPELRI ® , ampreloxetine and retained potential significant TRELEGY value • Strong, debt - free balance sheet • Finalizing capital return program • Sustainable, annual cash flow generation 2023 • Experienced Board and Management team with the right mix of skills and experience to drive value 5
Theravance Biopharma: Key Pillars of Value 6 MSA, multiple system atrophy; nOH , neurogenic orthostatic hypotension. Ampreloxetine in MSA Substantial opportunity for further growth in sizeable niche addressable patient population Investigational compound with potential to markedly differentiate from other treatment options offering hope to MSA patients with symptomatic nOH Retained potential significant future value of TRELEGY in milestones and outer year royalties Three distinct drivers of value over the near - , mid - , and long - term Retained Value Theravance is well positioned to maximize the value of its assets from a position of financial strength
FDA - approved for maintenance treatment of COPD First and only once - daily, LAMA (long - acting muscarinic agent) nebulized maintenance medicine for COPD 7 35% 65%
YUPELRI ® Hospital Sales and Community TRx Trends 8 1. Joint VTRS/TBPH Market Research. * Hospital LA - NEB Market Share - IQVIA DDD through 6/30/2022. †Community LA - NEB Market Share includes Retail + DME / Med B FFS through Apr’22 ǂ Retail TRx Volume - Symphony Health METYS Prescription Dashboard through 6/30/2022. Continued market share growth across both the hospital and retail channels 2.2% 3.4% 5.4% 6.5% 6.6% 7.4% 7.8% 8.7% 9.5% 10.8% 11.3% 11.9% 0% 5% 10% 15% 20% 25% 30% Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Hospital LA - NEB Market Share* YUPELRI LA-NEB Market Share TRx volume represents retail only which is typically 33% of Retail + DME Reported DME volume, while lagged, typically follows Retail volume trends 9.8% 13.1% 15.2% 16.3% 17.4% 18.7% 19.7% 21.4% 22.5% 23.2% 24.1% 25.3% 0K 5K 10K 15K 20K 25K 0% 5% 10% 15% 20% 25% 30% Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Retail TRx Volume ǂ Community LA - NEB Market Share † Retail TRx YUPELRI LA-NEB Market Share Most patients who receive YUPELRI ® in the hospital are discharged with an Rx 1 LA - NEB Market: YUPELRI, BROVANA , LONHALA , PERFOROMIST , arformoterol , formoterol Hospital Market Share Community Market Share with TRx
$12.9 $14.6 $13.8 $15.3 $15.3 $17.2 0 4 8 12 16 20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 56,130 70,050 78,090 93,360 97,500 107,670 K 20 K 40 K 60 K 80 K 100 K 120 K Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 YUPELRI ® | Gaining Momentum in Sales and Hospital Volume 9 Source: IQVIA DDD , HDS, VA and Non - Reporting Hospital through 6/30/2022. See TBPH 10K filed February 28, 2022 for greater detail re TBPH implied 35%. Quarterly YUPELRI Hospital Doses Doses sold increased 54% Q2’22 vs. Q2’21 TBPH Implied 35% of Total Net Sales ($M) Net sales increased 17% Q2’22 vs. Q2’21
1. American Lung Association. 2. Clarivate COPD Disease Landscape & Forecast US 2021. 3. Revefenacin COPD Joint Venture Research 2016 & Symphony Health Metys . 4. Safka KA, et al. Chronic Obstr Pulm Dis 2017. 5. Estimated from IQVIA XPO and SolutionsRx Med B FFS prescription volume. 6. Trinity US YUPELRI Market Research May 2022. COPD, chronic obstructive pulmonary disease; LAMA, long - acting muscarinic antagonist; PIFR, peak inspiratory flow rate. Substantial Opportunity for Further YUPELRI ® Growth 10 Once - Daily Nebulized LAMA COPD treatment represents a sizeable niche market Estimated COPD Patient Funnel (US) Estimated YUPELRI Potential Addressable Population ~250K ~3.5M ~5.25M Current Long - Acting Nebulized Patients 5 Handheld - Only Maintenance Patients for whom YUPELRI Therapy May Be Appropriate* ~8.75M maintenance patients using handheld treatments ~3.75M Addressable Population ~40%* Uncontrolled *Based on patient segments having difficulty using handheld treatments, including low PIFR , dexterity or cognitive challenges not already receiving nebulized maintenance treatment; patient subsets may not all be mutually exclusive; however, additional subsets not included may have difficulties with handhelds 6 LAMAs Considered Foundational, First - Line Treatment for Moderate - to - Very - Severe
Randomization 1:1 2H ’23 Results YUPELRI SPIRIVA ® via HH* Once - daily treatment: 12 weeks N=488 Run - in YUPELRI ® : Phase 4 Randomized, Double - blind, Parallel - group Study (PIFR - 2) 11 Phase 4, Randomized, Double - Blind, Parallel ˗ Group Study in Adults With Severe - to - Very - Severe COPD and Suboptimal Inspiratory Flow Rate. *Dry powder inhaler (Spiriva ® HandiHaler ® ). FEV 1 , forced expiratory volume in 1 second; PIFR, peak inspiratory flow rate. Endpoints ‣ Primary: Change from baseline in trough FEV 1 on Day 85 ‣ Key secondary: Trough overall treatment effect on FEV 1 Sample size increased from 366 to 488 through a pre - specified per - protocol blinded sample size re - estimation with no effect on a lpha.
Ampreloxetine (TD - 9855) Investigational once - daily norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension in multiple system atrophy patients 12
Offering Hope to MSA Patients with Symptomatic nOH 13 1. 2019 IQVIA Claims Analysis; NIH; 2. Mathias CJ, et al. J Neurol 1999 Oct;246(10):893 - 8; 3. Data from MSA patients after 4 wee ks of ampreloxetine administration in study 0169. 4. Data from MSA patients at week 6 of the randomized withdrawal period of study 0170. 5. Palma JA, Kaufmann H. Mov Disord Clin Pract 2017;4:298 - 308. MSA, multiple system atrophy; nOH , neurogenic orthostatic hypotension. nOH Prevalence in MSA Patients • ~50K MSA patients in US 1 (meets orphan disease criteria) • 70 – 90% of MSA patients experience nOH symptoms 2 • Despite available therapies, many MSA patients remain symptomatic with nOH Prevents blood pressure drop and symptoms worsening in MSA 3,4 x Increased standing blood pressure x Increased brain perfusion x Reduce symptoms of symptomatic nOH 5 Untreated nOH Syncope Normal + Ampreloxetine Reduction in Syncope Normal
Offering Hope to MSA Patients with Symptomatic nOH Potential for ampreloxetine to differentiate from approved therapies 14 1. Reflects Theravance Biopharma's expectations for ampreloxetine based on clinical trial data to date. Ampreloxetine is in development and not approved for any indication. Data on file. MOA, mechanism of action; MSA, multiple system atrophy; nOH , neurogenic orthostatic hypotension; OH, orthostatic hypotension; OHSA, orthostatic hypotension symptom assessment. Droxidopa Midodrine Ampreloxetine 1 Indication Symptomatic nOH OH Symptomatic nOH associated with MSA MOA Norepinephrine prodrug; vasoconstrictor Desglymidodrine prodrug; alpha 1 - receptor agonist; vasoconstrictor Norepinephrine transporter reuptake inhibitor Dosing 3x daily, titration to effect 3x daily Once - daily Clinical Efficacy/ Durability OHSA#1, clinical effectiveness >2 weeks not established Increase in systolic blood pressure 1 min after standing OHSA composite; clinically meaningful and durable response over 22 weeks Clinical Safety Black box warning for supine hypertension No signal for supine hypertension in safety database of >800 patients and healthy subjects
Offering Hope to MSA Patients with Symptomatic nOH 15 33rd International Symposium on the Autonomic Nervous System November 2 – 5, 2022: Sheraton Maui, Lahaina, Hawaii Kaufmann H, et al. Abstract 33 / Virtual Poster 117 Blood pressure and pharmacodynamic response of ampreloxetine, a norepinephrine reuptake inhibitor, in patients with symptomatic nOH Biaggioni I, et al. Abstract 34 / Virtual Poster 106 A phase 3, 22 - week, multi - center, randomized withdrawal study of ampreloxetine in treating symptomatic nOH Freeman R, et al. Abstract 30 / Virtual Poster 4 Longitudinal analysis of ampreloxetine for the treatment of symptomatic nOH in subset of patients with MSA Platform Presentations MSA, multiple system atrophy; nOH , neurogenic orthostatic hypotension.
Phase 3 randomized withdrawal study in patients with MSA Primary endpoint: change in OHSA composite score Offering Hope to MSA Patients with Symptomatic nOH 16 MSA, multiple system atrophy; nOH , neurogenic orthostatic hypotension; OHSA, orthostatic hypotension symptom assessment; RWD, randomized withdrawal design. Streamlined operational infrastructure Optimized country/site selection Randomization 1:1 Results Ampreloxetine 10 mg Placebo Once - daily treatment Ampreloxetine 10 mg Open - Label Once - daily treatment Double - blind RWD Q1’23 Entry
Sale of Economic Interest GSK’s TRELEGY ELLIPTA (FF/UMEC/VI): Once - daily single inhaler triple therapy 17
Retained Value of Theravance Biopharma’s 85% TRELEGY ELLIPTA Interest 1 18 1. All of its units in Theravance Respiratory Company, LLC. 2. The first milestone payment, of $50.0 million, will be triggered if Royalty Pharma receives $240.0 million or more in royalty pa yments from GSK with respect to 2023 TRELEGY global net sales, which we would expect to occur in the event TRELEGY global net sales reach approximately $2 .86 3 billion. 3. 85 % of TRELEGY ELLIPTA royalties return to Theravance Biopharma beginning July 1, ௗ 2029 ௗ for sales ex - U.S., and January 1, ௗ 2031 ௗ for sales within the U.S. ௗ Net present value (“NPV”) of royalties based on GSK Bloomberg Consensus for TRELEGY ELLIPTA through 2032 for U.S. sales and through 2034 for ex - U.S. sales, discounted at 7%. Ex - U.S. sales for 2033 - 2034 extrapolated by Management due to limitation of co nsensus beyond 2032. Upfront: ~$1.1B cash Mid - Term : Up to $250M Long - Term: ~$200M 3 Over $1.5 Billion in potential total value to Company shareholders • Will be paid to TBPH directly from Royalty Pharma • Estimated NPV • TRELEGY ELLIPTA sales - based milestones between 2023 – 2026 • First milestone in 2023 ($50M) for Global Net Sales of $2.863B 2 – Q2’22 actuals of $591M up 46% from Q2'21 Retain long - term value in TRELEGY ELLIPTA royalty interest Additional value from continued TRELEGY ELLIPTA performance Unlocks and accelerates capture of TRELEGY ELLIPTA value GSK remains exclusively responsible for commercialization of TRELEGY ELLIPTA
TRELEGY ELLIPTA Theravance Biopharma and Royalty Pharma Deal Summary • Upfront: $1.1B • Milestones: Up to $250M 1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. U.S. royalties expected to end late 2032; ex - U.S. royalties expected to end mid - 2030s and are country specific. Ampreloxetine (Unsecured Royalty) 4. Net present value (“NPV”) of royalties based on GSK Bloomberg Consensus for ELLIPTA through 2032 for U.S. sales and through 2034 for ex - U.S. sales, discounted at 7%. Ex - U.S. sales for 2033 - 2034 extrapolated by Management due to limitation of consensus beyond 2032. 19 • Outer Year Royalty (“OYR”): 85% of royalties for TRELEGY ELLIPTA return to Theravance Biopharma: – On and after January 1, ௗ 2031 ௗ for U.S. sales 3 – On and after July 1, ௗ 2029 ௗ for ex - U.S. sales 3 – NPV estimated at ~$200M 4 • Upfront payment: $25M • 1st Regulatory approval milestone: $15M – Approval by either FDA or first of the EMA or all four Germany, France, Italy and Spain • Future royalties paid to Royalty Pharma: – 2.5% on annual global net sales up to $500M – 4.5% on annual global net sales > $500M
Financial Guidance • Reiterating 2022 OPEX guidance: – R&D: range of $45 – 55M – SG&A: range of $35 – 45M • 2022 guidance includes ~$10M in non - recurring spend: – Majority in Q1 to support completion of late - stage programs – OPEX Q3 and onward will reflect recurring spend only • Guidance excludes : – Non - cash share - based compensation (SBC) – One - time restructuring, severance & termination costs • ~ $11.7M in 2022 ($9.3M 2 Q1 / $1.6M 3 Q2 / $0.8M 4 Q3 / $0M 4 Q4) – One - time transaction related costs of $5.1M YTD 20 1.) Excludes non - cash share - based compensation (SBC), one - time restructuring, severance and termination costs, and one - time tran saction related legal expenses. 2.) $4.8M of cash related expenses and $4.5M of non - cash expenses. 3.) $1.2M of cash related expenses and $0.4M of non - cash expenses. 4 .) Q3 / Q4 are estimates and subject to change; primarily comprised of non - cash expenses. Theravance Biopharma expects to approach breakeven cash flow from operations in 2H 2022 and become sustainably cash flow positive going forward on an annual basis 168 50 71 40 2021 Actuals 2022 Guidance SG&A R&D 2021 Actuals vs. 2022 Guidance Mid - Point OPEX ($M) 1 239 90
Rick E Winningham Chairman and Chief Executive Officer Former CEO, Theravance, Inc. (now INVA) Former President (Oncology/ Immunology/Oncology Therapeutics Network), Bristol Myers Squibb Andrew A. Hindman Senior Vice President, Chief Financial Officer Former Chief Business Officer, Acorda Therapeutics Former President & CEO, Tobira Therapeutics Rhonda F. Farnum Senior Vice President, Chief Business Officer Former Executive Director of Marketing, Amgen Former VP (Hematology), Onyx Pharmaceuticals & Former Commercial Leadership, Genentech Richard A. Graham Senior Vice President, Research and Development Former Senior Director, Head of Translational Medicine, Onyx Pharmaceuticals Former Clinical Pharmacologist and Project Team Leader, Genentech and GlaxoSmithKline Brett A. Grimaud Senior Vice President, General Counsel and Secretary Former Senior Director, Theravance , Inc. (now INVA) F ormer Senior Attorney, Gunderson Dettmer An Experienced Leadership Team Stacy Pryce Senior Vice President, Chief Strategy Officer Former VP Business Development, Aerogen Former Senior Director, Alliance Management & Business Development Vertex Pharmaceuticals 21
The Board of Directors Experienced leaders from a diverse range of relevant backgrounds 22 Dean Mitchell Former President & CEO, Lux Biosciences • Extensive management experience in the pharmaceutical and biotherapeutics industries with expertise in later stage drug development and commercialization • Former President & CEO at Alpharma and Guilford Pharmaceuticals Donal O’Connor Former Senior Partner, PwC Ireland • Extensive experience across the financial and pharmaceutical industries, including with Irish entities, in addition to accounting and financial expertise • Former Chairman of Anglo Irish Bank and Board member at the Irish Auditing and Accountancy Supervisory Authority Deepa Pakianathan, Ph.D. CEO, Redd Pharmaceuticals • Knowledge and experience in overseeing the business development and strategy of multiple healthcare companies with experience gained as a biotechnology investor, research analyst and research scientist • Managing Member at Delphi Ventures William Young Senior Advisor, Blackstone Life Sciences • Extensive leadership experience at numerous pharmaceutical and biotechnology organizations as well as financial / investing expertise gained as a venture capitalist • Former Chairman & CEO at Monogram Biosciences and Venture Partner at Claris Ventures Rick Winningham Chairman & CEO, Theravance Biopharma • Demonstrated leadership and senior management experience in the biopharmaceutical industry • Former Chairman & CEO at Theravance, Inc. (now INVA) and former President of Oncology / Immunology / Oncology Therapeutics Network and President of Global Marketing at Bristol Myers Squibb Laurie Smaldone Alsup, M.D. Chief Medical & Chief Scientific Officer, NDA Group • Extensive leadership experience with regulatory and clinical expertise in the life sciences industry • Former President and Chief Scientific Officer at PharmApprove and CEO at Phytomedics Eran Broshy Former Chairman & CEO, inVentiv Health • Demonstrated leadership in managed healthcare in addition to the broader healthcare industry • Former Partner and Head of the Americas Healthcare Practice at The Boston Consulting Group and CEO at Coelacanth Burton Malkiel, Ph.D. CIO & Chair of the Investment Committee, Wealthfront • Demonstrated leadership and knowledge of financial and financing matters • Former Appointee to the President’s Council of Economic Advisors
Investment Highlights • Transformed and focused therapeutics company • Attractive pipeline and programs with YUPELRI ® , ampreloxetine and retained potential significant TRELEGY value • Strong, debt - free balance sheet • Finalizing capital return program • Sustainable, annual cash flow generation 2023 • Experienced Board and Management team with the right mix of skills and experience to drive value 23
YUPELRI ® (revefenacin) inhalation solution YUPELRI ® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . Important Safety Information (US) YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product . YUPELRI should not be initiated in patients during acutely deteriorating or potentially life - threatening episodes of COPD, or for the relief of acute symptoms, i . e . , as rescue therapy for the treatment of acute episodes of bronchospasm . Acute symptoms should be treated with an inhaled short - acting beta 2 - agonist . As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life - threatening . If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short - acting bronchodilator . YUPELRI should be discontinued immediately and alternative therapy should be instituted . YUPELRI should be used with caution in patients with narrow - angle glaucoma . Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow - angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema . Worsening of urinary retention may occur . Use with caution in patients with prostatic hyperplasia or bladder - neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur . Immediate hypersensitivity reactions may occur after administration of YUPELRI . If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered . The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2 % in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain . Coadministration of anticholinergic medicines or OATP 1 B 1 and OATP 1 B 3 inhibitors with YUPELRI is not recommended . YUPELRI is not recommended in patients with any degree of hepatic impairment . OATP, organic anion transporting polypeptide. 24
About YUPELRI ® (revefenacin) inhalation solution YUPELRI ® ( revefenacin ) inhalation solution is a once - daily nebulized LAMA approved for the maintenance treatment of COPD in the US . Market research by Theravance Biopharma indicates approximately 9 % of the treated COPD patients in the US use nebulizers for ongoing maintenance therapy . 1 LAMAs are a cornerstone of maintenance therapy for COPD and YUPELRI ® is positioned as the first once - daily single - agent bronchodilator product for COPD patients who require, or prefer, nebulized therapy . YUPELRI ® ’s stability in both metered dose inhaler and dry powder device formulations suggest that this LAMA could also serve as a foundation for novel handheld combination products . 1. TBPH market research (N=160 physicians); refers to US COPD patients. COPD, chronic obstructive pulmonary disease; LAMA, long - acting muscarinic antagonist. 25